Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the . We combine our deep understanding of metabolic pathways, our unique EMM-focused database and recent advances in technology and systems biology to design novel product candidates with the potential to have a profound impact on complex diseases and support health. View HTML. Initial filing by director officer or owner of more than ten percent. Our net . Hes not willing to live in my house because it has fewer amenities: My boyfriend wants me to move in and pay half his monthly costs. AXLA Valuations. Endogenous Metabolic Modulators. This browser is no longer supported at MarketWatch. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8 . We are publishing innovative research and presenting at leading conferences. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. 2021 Quotemedia. AXLA Annual Reports. E: info@axcellatx.com, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA. Many, but not all SEC filings are available in the SECs EDGAR database. SEC Filings. Do Not Sell My Personal Information (CA Residents Only). Document Details. By using this site you agree to the AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) . Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Have Watchlists? SEC filings and transcripts for Axcella Health Inc, including financials, news, proxies, indentures, prospectuses, . Inside Axcella Health Inc.'s 10-K Annual Report: Other - Other Highlight. Axcella Health Inc. - 10-Q, Quarterly Report-SEC Filings: Di: Axcella Health Inc. - 8-K, Current Report-SEC Filings: Di: Axcella Reports Third Quarter Financial Results and Provides Business . 0001104659-22-085175.pdf. Our lead product candidates are for liver diseases. Copyright 2022 MarketWatch, Inc. All rights reserved. Historical and current end-of-day data provided by FACTSET. MA 02139, O: 857-320-2200 Nasdaq provides companysSEC filings, which arefinancial statements andreports filed electronically with the U.S. Securities and Exchange Commission (SEC) byQuotemedia. Download PDF. Axcella Health Inc. SEC filings breakout by MarketWatch. View HTML. Endogenous Metabolic Modulators, or EMMs, are a critical set of molecules that are fundamental to biology. EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION . They serve as master regulators and signaling agents for metabolic pathways throughout the body. Diesel shortage keeps fuel prices high at the pump. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. Initial filing by director officer or owner of more than ten percent. SEC Filings Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - 2022 2021 2020 2019 2018 2017 2016 2015 The SEC requires all publicly traded companies, foreign and domestic, to disclose financial condition, operating results, management compensation, and other areas of their business on a regular basis. MA 02139, O: 857-320-2200 Correspondence with the SEC 06/10/20 UPLOAD Letter from the SEC 06/10/20 EFFECT Notice of effectiveness 05/13/20 CORRESP . Report of unscheduled material events or corporate event, Quarterly report which provides a continuing view of a company's financial position, Statement of changes in beneficial ownership of securities. Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3, 840 Memorial Drive, Date of Report (Date of earliest event reported): August 12, 2019 _____ AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) . 0001104659-22-085175.rtf. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA. 0000899243-22-033691.xls. Form. Axcella Health Inc. (AXLA) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021. Download XLS. Issuer. MA 02139, O: 857-320-2200 Axcella Health Inc is primarely in the business of biological products (no diagnostic substances). Something went wrong while loading Watchlist. Oct 17, 2022. Statement of changes in beneficial ownership of securities. Notice is hereby given that the 2022 Annual Meeting of Stockholders, or Annual Meeting, of Axcella Health Inc. (d/b/a Axcella Therapeutics) (the "Company" or "Axcella"), which will be a virtual-only meeting to be held on May 19, 2022, at 10:00 A.M. Eastern Time. Cookie Notice (). Axcella Health Inc. (AXLA) 10-K Annual Report Wed Mar 30 2022; . Type a symbol or company name. Filing date Description Form Filing Group View; Aug 02, 2022: Report of unscheduled material events or corporate event. XBRL. SEC Filings. 10-K Annual Report March 2022 10-K Annual Report March 2021 10-K Annual . Pioneering a new approach to treating complex diseases using Endogenous Metabolic Modulators (EMMs). Intrinsic Value. Axcella Health Inc. (AXLA) SEC Filing 8-K Material Event for the period ending Tuesday, November 1, 2022. . When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Palantir stock falls after earnings as revenue growth slows, U.S. seizes Bitcoin once valued at $3.4 billion that real-estate developer stole from dark web a decade ago, The Powerball jackpot is now $1.9 billion, setting another record, The turkey is non-negotiable: Americans refuse to skimp on Thanksgiving Day turkey, despite soaring food prices. 10-Q Filing Date. For financial reporting, their fiscal year ends on December 31st. Items per page. F: 617-441-6243 3rd Floor, Cambridge, Find the latest Axcella Health Inc. (AXLA) stock quote, history, news and other vital information to help you with your stock trading and investing. . Insider Trades. We have built a strong leadership team with deep biopharma expertise. Axcella Health Inc. SEC filings breakout by MarketWatch. Initial filing by director officer or owner of more than ten percent. 10-K Annual Report March 2022 10-K Annual Report March 2021 10-K Annual Report . EMMs encompass a broad set of molecular families, including amino acids and their derivatives. When autocomplete results are available use up and down arrows to review and enter to select. Find out about Axcellas latest accomplishments and upcoming events. All quotes are in local exchange time. Financial Ratios. Is that fair? Financial Results: Cash Position: As of September 30, 2022, cash, cash equivalents, and marketable securities totaled $25.4 million, compared to $55.0 million as of December 31, 2021. 8-K: Current Reports. Endogenous Metabolic Modulators, or EMMs, are a critical set of molecules that are fundamental to biology. 0000899243-22-033691.rtf. SEC Filing Details SEC Filing Details. See AXA1125s potential impact on Long COVID, Read about AXA1125s Fast Track Designation in NASH, Learn about our EMMPACT clinical trial in NASH, See how compositions of endogenous metabolic modulators (EMMs) can be utilized for complex diseases. Notifications. F: 617-441-6243 Financial Stability. Intraday data delayed at least 15 minutes or per exchange requirements. Filing year. Business Wire. Create a list of the investments you want to track. Intraday Data provided by FACTSET and subject to terms of use. However, if we or any of the third parties with whom we engage were to . SEC Filings SEC Filings Group. Home. Find the latest SEC Filings data for Axcella Health Inc. Common Stock (AXLA) at Nasdaq.com. E: info@axcellatx.com. below): . Manager Portfolios. 2022, Nasdaq, Inc. All Rights Reserved. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. They serve as master regulators and signaling agents for metabolic pathways throughout the body. Intrinsic Value. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. 0000899243-22-033691.pdf. AXLA Annual Reports. Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3, 840 Memorial Drive, SEC Filings. Create your Watchlist to save your favorite quotes on Nasdaq.com. View the AXLA U.S. Securities and Exchange Commission reporting information. AXLA Valuations. 8-K 1 axcella_06302019x8k.htm 8-K . Axcella Therapeutics. Copy and paste multiple symbols separated by spaces. Insider Trades. View the AXLA U.S. Securities and Exchange Commission reporting information. EX-101.SCH - XBRL TAXONOMY . These symbols will be available throughout the site during your session. Type a symbol or company name. 3rd Floor, Cambridge, Log in to see them here or sign up to get started. Financial Ratios. Report of unscheduled material events or corporate event, Quarterly report which provides a continuing view of a company's financial position, Statement of changes in beneficial ownership of securities. Axcella's net loss for the quarter and nine months ended September 30, 2022, was $17.8 million, or $0.34 per basic and diluted share, and $58.2 million or $1.19 per share, respectively. We value bright minds, collaborative approaches and energetic spirits. Quotemediais not affiliated with or approved by the U.S. Securities and Exchange Commission. Manager Portfolios. EMMs encompass a broad set of molecular families, including amino acids and their derivatives. Axcella Health Inc. (AXLA) SEC Filing 10-Q Quarterly Report for the period ending Friday, September 30, 2022. . Axcella Health Inc. is incorporated in the state of Delaware. . Visit a quote page and your recently viewed tickers will be displayed here. 3rd Floor, Cambridge, Nov 1, 2022. Axcella Health Inc. (AXLA) - DEFA14A - Additional Proxy Soliciting Materials (definitive) In September 2022, the Company received $6.0 million from the issuance of convertible notes to funds associated with Flagship Pioneering and, in October 2022, the . E: info@axcellatx.com, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA. Financial Stability. 0001104659-22-085175.xls. Touch device users, explore by touch or with swipe gestures. There are currently no items in this Watchlist. Notifications. The purpose of the virtual Annual Meeting is the following: Document Date. This information can be used by investors to verify and understand the financial position of the company. The clinical data we have generated to date support the potential for our therapeutic product candidates to simultaneously influence multiple biologies relevant to complex diseases with a favorable safety profile. Subscriber Agreement & Terms of Use, Axcella Health Inc. Filing Formats. 4. XBRL Viewer. F: 617-441-6243 840 Memorial Drive, 3,4,5. SEC Filings. Privacy Notice, and For the best MarketWatch.com experience, please update to a modern browser. Download DOC. If you have questions about the Special Meeting or the proposals to be presented thereat, if you need additional copies of the proxy statement or the enclosed proxy card or if you would like copies of any of the Company's filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021, and our subsequent .